Kenvue Slips 5.7% vs Nasdaq's 19.5% Gain
The company's shares have underperformed the Nasdaq Composite over the past year, with margin pressure and legal uncertainty surrounding Tylenol contributing to the decline, including a 1.8% drop after a federal appeals court revived over 500 lawsuits
Kenvue Inc. (KVUE) has underperformed the Nasdaq Composite over the past year, with its shares declining 5.7% compared to the Nasdaq's 19.5% gain. The company's market capitalization stands at approximately $34.1 billion.
Kenvue's shares have slipped 11.7% from their 52-week high of $20.13, reached on July 7, 2026. Despite gaining 3.1% year-to-date, the company's shares have struggled to keep pace with the broader market. Over the past 52 weeks, Kenvue's shares have declined 5.7%, while the Nasdaq Composite has returned 19.5%.
The company's recent performance has been impacted by margin pressure and legal uncertainty surrounding Tylenol. On July 13, a federal appeals court revived over 500 private lawsuits alleging a link between Tylenol use during pregnancy and autism and ADHD. Following the news, Kenvue's shares fell 1.8% in afternoon trading.
## Why it matters Kenvue's underperformance relative to the Nasdaq Composite is significant, given the company's size and influence in the household and personal products industry. As a large-cap stock with a market capitalization of over $34 billion, Kenvue's performance is closely watched by investors. The company's trusted consumer health brands and promising momentum in Skin Health and Beauty are positives, but the ongoing legal uncertainty surrounding Tylenol and margin pressure are likely to continue weighing on the stock.
The Nasdaq Composite's 19.5% gain over the past 52 weeks highlights the broader market's strength, making Kenvue's 5.7% decline stand out. As the company navigates these challenges, investors will be closely watching its progress and any developments in the Tylenol lawsuits.
